SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Pelthos Therapeutics Posts $15.2 Million Q3 Revenue, Net Loss Narrows to $7.9 Million

Pelthos Therapeutics reported third-quarter 2026 revenue of $15.4 million, including $15.2 million in Zelsuvmi net product revenue, up 114% year over year. Net loss narrowed to $7.9 million from $16.2 million a year earlier, while Adjusted EBITDA was a loss of $5.6 million. The company also provide…

PTHS

Related stories